330 related articles for article (PubMed ID: 26114155)
21. The anti-oxidative transcription factor Nuclear factor E2 related factor-2 (Nrf2) counteracts TGF-β1 mediated growth inhibition of pancreatic ductal epithelial cells -Nrf2 as determinant of pro-tumorigenic functions of TGF-β1.
Genrich G; Kruppa M; Lenk L; Helm O; Broich A; Freitag-Wolf S; Röcken C; Sipos B; Schäfer H; Sebens S
BMC Cancer; 2016 Feb; 16():155. PubMed ID: 26915435
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells.
Pelosi E; Castelli G; Testa U
Biomedicines; 2017 Nov; 5(4):. PubMed ID: 29156578
[TBL] [Abstract][Full Text] [Related]
23. Nitric oxide and pancreatic cancer pathogenesis, prevention, and treatment.
Wang L; Xie K
Curr Pharm Des; 2010; 16(4):421-7. PubMed ID: 20236070
[TBL] [Abstract][Full Text] [Related]
24. IL2RG, identified as overexpressed by RNA-seq profiling of pancreatic intraepithelial neoplasia, mediates pancreatic cancer growth.
Ayars M; O'Sullivan E; Macgregor-Das A; Shindo K; Kim H; Borges M; Yu J; Hruban RH; Goggins M
Oncotarget; 2017 Oct; 8(48):83370-83383. PubMed ID: 29137350
[TBL] [Abstract][Full Text] [Related]
25. Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.
Fendrich V; Sparn M; Lauth M; Knoop R; Plassmeier L; Bartsch DK; Waldmann J
Pancreatology; 2013; 13(5):502-7. PubMed ID: 24075515
[TBL] [Abstract][Full Text] [Related]
26. Pancreatic cancer: Stroma and its current and emerging targeted therapies.
Kota J; Hancock J; Kwon J; Korc M
Cancer Lett; 2017 Apr; 391():38-49. PubMed ID: 28093284
[TBL] [Abstract][Full Text] [Related]
27. Genetic progression of pancreatic cancer.
Cowan RW; Maitra A
Cancer J; 2014; 20(1):80-4. PubMed ID: 24445769
[TBL] [Abstract][Full Text] [Related]
28. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk.
Orozco CA; Martinez-Bosch N; Guerrero PE; Vinaixa J; Dalotto-Moreno T; Iglesias M; Moreno M; Djurec M; Poirier F; Gabius HJ; Fernandez-Zapico ME; Hwang RF; Guerra C; Rabinovich GA; Navarro P
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):E3769-E3778. PubMed ID: 29615514
[TBL] [Abstract][Full Text] [Related]
29. Precursor lesions of pancreatic cancer: molecular pathology and clinical implications.
Singh M; Maitra A
Pancreatology; 2007; 7(1):9-19. PubMed ID: 17449961
[TBL] [Abstract][Full Text] [Related]
30. Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma.
Fox RG; Lytle NK; Jaquish DV; Park FD; Ito T; Bajaj J; Koechlein CS; Zimdahl B; Yano M; Kopp J; Kritzik M; Sicklick J; Sander M; Grandgenett PM; Hollingsworth MA; Shibata S; Pizzo D; Valasek M; Sasik R; Scadeng M; Okano H; Kim Y; MacLeod AR; Lowy AM; Reya T
Nature; 2016 Jun; 534(7607):407-411. PubMed ID: 27281208
[TBL] [Abstract][Full Text] [Related]
31. [Intraepithelial neoplasms (PanIN) and intraductal papillary-mucinous neoplasms (IPMN) of the pancreas as precursor lesions of pancreatic carcinoma].
Ott C; Heinmöller E; Gaumann A; Schölmerich J; Klebl F
Med Klin (Munich); 2007 Feb; 102(2):127-35. PubMed ID: 17323019
[TBL] [Abstract][Full Text] [Related]
32. The role of stromal cancer-associated fibroblasts in pancreatic cancer.
von Ahrens D; Bhagat TD; Nagrath D; Maitra A; Verma A
J Hematol Oncol; 2017 Mar; 10(1):76. PubMed ID: 28351381
[TBL] [Abstract][Full Text] [Related]
33. Pancreatic intraepithelial neoplasia.
Takaori K; Hruban RH; Maitra A; Tanigawa N
Pancreas; 2004 Apr; 28(3):257-62. PubMed ID: 15084967
[TBL] [Abstract][Full Text] [Related]
34. Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions.
Hermanova M; Trna J; Nenutil R; Dite P; Kala Z
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):732-9. PubMed ID: 18617777
[TBL] [Abstract][Full Text] [Related]
35. Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma.
Zhu J; Wu J; Pei X; Tan Z; Shi J; Lubman DM
PLoS One; 2017; 12(4):e0175039. PubMed ID: 28369074
[TBL] [Abstract][Full Text] [Related]
36. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications.
Goggins M; Hruban RH; Kern SE
Am J Pathol; 2000 May; 156(5):1767-71. PubMed ID: 10793087
[TBL] [Abstract][Full Text] [Related]
37. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms.
Hruban RH; Takaori K; Klimstra DS; Adsay NV; Albores-Saavedra J; Biankin AV; Biankin SA; Compton C; Fukushima N; Furukawa T; Goggins M; Kato Y; Klöppel G; Longnecker DS; Lüttges J; Maitra A; Offerhaus GJ; Shimizu M; Yonezawa S
Am J Surg Pathol; 2004 Aug; 28(8):977-87. PubMed ID: 15252303
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological features of pancreatic intraepithelial neoplasias and their relationship to intraductal papillary-mucinous tumors.
Takaori K; Kobashi Y; Matsusue S; Matsui K; Yamamoto T
J Hepatobiliary Pancreat Surg; 2003; 10(2):125-36. PubMed ID: 14505145
[TBL] [Abstract][Full Text] [Related]
39. The molecular genetics of pancreatic ductal carcinoma.
Sohn TA
Minerva Chir; 2002 Oct; 57(5):561-74. PubMed ID: 12370658
[TBL] [Abstract][Full Text] [Related]
40. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.
Adsay NV; Basturk O; Cheng JD; Andea AA
Semin Radiat Oncol; 2005 Oct; 15(4):254-64. PubMed ID: 16183479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
